Reaction
Renal Cell Carcinoma Recurrent reporting signals
As of the last recalculation, Renal Cell Carcinoma Recurrent appears in 113 FAERS reports alongside 3 co-occurring drug terms. The strongest observed disproportionality signal is PAZOPANIB HYDROCHLORIDE (PRR 82.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pazopanib Hydrochloride | 11 | 82.8 | 82.9 |
| Cabozantinib | 15 | 66.2 | 66.2 |
| Axitinib | 6 | 59.9 | 59.9 |